Orphan drug status for brain-cancer delivery device; Echo completes Prelude SkinPrep trials;

> The FDA has granted orphan drug status to a brain-cancer delivery device developed by the Dutch company to-BBB. The product, 2B3-101, uses glutathione to enhance delivery of Caelyx/Doxil (PEG-liposomal doxorubicin) across the blood-brain barrier, according to the company. to-BBB release

> Echo Therapeutics, based in Franklin, MA, has announced successful completion of clinical trials for its Prelude SkinPrep System for transdermal drug delivery of lidocain cream for fast-acting local dermal anesthesia. The study evaluated the ability of Prelude to ablate the skin prior to the application of lidocaine cream. Next step, getting market clearance from the FDA to launch the product. Echo release

> If you build drug-delivery vehicles layer by layer, you can encapsulate a high payload of drugs, readily engineered with specific properties. The journal Small has a review of layer-by-layer assembly, including drug-loading methods and delivery routes. Abstract 

> Drug Delivery Technology magazine exclaims in a special feature in the July/August edition: "Transdermal Delivery--Making a Comeback!" Article

Drug delivery patent of the week: Method of manufacturing hydroxyapatite and uses therefor in delivery of nucleic acids. Patent

Drug Delivery Tweet of the Week: @a_mahapatra Overhead: A PI talking about a drug delivery system. No one looks up when he says "buckyballs" because everyone's a chemist #ACS_Boston. Tweet

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.